Core Viewpoint - Cloud-based innovative pharmaceutical company, CloudTop New Medicine, has signed an exclusive licensing agreement with Visara to develop, produce, and commercialize VIS-101 in Greater China, Singapore, South Korea, and several Southeast Asian countries, marking a significant entry into the ophthalmic treatment market valued at over 100 billion [1][2]. Group 1: Company Developments - CloudTop New Medicine will pay a total of $7 million (approximately 49.7 million RMB) as an upfront payment, along with potential milestone payments up to $89 million (approximately 632 million RMB) based on development and sales achievements [1]. - The CEO of CloudTop New Medicine emphasized the company's commitment to leveraging its clinical development capabilities to expedite the clinical development and commercialization of VIS-101 in China and Asia [1][2]. - The strategic partnership with Visara is expected to enhance CloudTop's product pipeline and expand its business into the ophthalmic sector, which has unmet clinical needs [3]. Group 2: Product and Market Insights - VIS-101 is a novel dual-function biologic targeting VEGF-A and ANG-2, showing improved efficacy over first-generation treatments for conditions like wet AMD, DME, and RVO [2]. - The global anti-VEGF ophthalmic drug market is projected to grow from approximately $23 billion in 2024 to over $40 billion by 2030, driven by significant unmet clinical needs in retinal disease treatments [2]. - In China alone, the number of existing and new patients with wet AMD and DME exceeds 15 million, with about 600,000 new cases annually, highlighting a substantial unmet clinical demand [2]. Group 3: Strategic Collaboration - Visara is a subsidiary of New Bridge Bio, which is listed on NASDAQ, and CloudTop New Medicine is the largest shareholder of New Bridge Bio [3]. - The collaboration aims to optimize global commercial layouts and promote clinical development synergies in Asia [3]. - CloudTop New Medicine plans to build a commercial platform based on its "dual-engine" strategy, focusing on CAR-T and mRNA therapeutic vaccine platforms to drive breakthrough developments in commercialization [3].
云顶新耀引进眼科双抗药物VIS-101 切入400亿美元眼科蓝海市场